Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: Results of a prematurely closed phase 2 study

Leukemia and Lymphoma

Volumn 56, Issue 11, 2015, Pages 3227-3229

  Schreiber, Susanne ^a   Hoellein, Alexander ^a   Decker, Thomas ^b   Jilg, Stefanie ^a   Dreyling, Martin ^c   Peschel, Christian ^a   Keller, Ulrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Oncology Ravensburg   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; ANTINEOPLASTIC AGENT;

ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION; LYMPHOMA, MANTLE-CELL; MAINTENANCE CHEMOTHERAPY; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EVEROLIMUS; HUMANS; LYMPHOMA, MANTLE-CELL; MAINTENANCE CHEMOTHERAPY; TREATMENT OUTCOME;

EID: 84947733980     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1028055     Document Type: Article

References (15)

1. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115-127.
2. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008; 142: 149-165.
3. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009; 2009: 542-551.
4. Gordon LI, Bernstein SH, Jares P, et al. Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma 2014; 55: 2262-2270.
5. Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: 83-92.
6. Borgerding A, Hasenkamp J, Glass B, et al. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol 2010; 89: 283-289.
7. Smith SM. Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract Res Clin Haematol 2012; 25: 175-183.
8. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108: 1668-1676.
9. Butler MP, Wang SI, Chaganti RS, et al. Analysis of PTEN mutations and deletions in B-cell non-Hodgkins lymphomas. Genes Chromosomes Cancer 1999; 24: 322-327.
10. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
11. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
12. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003-4008.
13. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
14. Witzens-Harig M, Hess G, Atta J, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol 2012; 91: 1765-1772.
15. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.